STRIDES PHARMA
GenericsSTRIDES PHARMA is a generic drug manufacturer focused on Infectious Disease, Neurology, Respiratory.
STRIDES PHARMA's Key Drugs
STRIDES PHARMA's core commercial portfolio centers on EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, spanning Infectious Disease and Neurology — its most strategically important drugs approved in the last 15 years.
STRIDES PHARMA's Recent FDA Approvals
New NDA/BLA approvals for STRIDES PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
STRIDES PHARMA's Therapeutic Areas
STRIDES PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
STRIDES PHARMA's Top Competitors
STRIDES PHARMA's closest competitors by therapeutic-area and drug-target overlap include Merck, GE HEALTHCARE, and Novo Nordisk. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
STRIDES PHARMA Pipeline Snapshot
Active clinical trials for STRIDES PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (1)
Company Info
- First Approval
- 1979-03-27
- Latest
- 2026-06-18
- Applications
- 112